With the experience gained over the past year in the generation of human monoclonal antibodies, we will continue our efforts in the following areas: (1) attempts to establish new human myeloma cell lines. New human partners are needed for humanhuman hybridomas. We will continue to culture myeloma specimen in a variety of conditions; (2) expansion of the number of human monoclonal antibodies to human cancer antigens. We will continue to develop new human monoclonal antibodies to both cell surface and intracellular antigens and begin to explore in vitro sensitization of immune lymphocytes; and (3) continuation of biochemical characterization of antigens detected by human monoclonal antibodies. Using Western blotting and immunoprecipitation of cells labeled with ?125?I, ?35?Smethionine, or ?3?H-glucosamine, we will study the biochemical characteristics of antigens. To date, these approaches have been most successful with antibodies recognizing cytoskeletal components of cells. (4) explore methods for large scale production and purification of a small number of human monoclonal antibodies with restricted reactivities in preparation for preclinical studies and clinical investigations in patients with cancer. (HI)

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Immunology Study Section (EI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Chapman, P B; Yuasa, H; Houghton, A N (1990) Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol 145:891-8
Chapman, P B; Lonberg, M; Houghton, A N (1990) Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res 50:1503-9
Eton, O; Scheinberg, D A; Houghton, A N (1989) Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia 3:729-35
Welt, S; Carswell, E A; Vogel, C W et al. (1987) Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 45:214-29
Real, F X; Rettig, W J; Chesa, P G et al. (1986) Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 46:4726-31
Cote, R J; Morrissey, D M; Houghton, A N et al. (1986) Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci U S A 83:2959-63
Dracopoli, N C; Houghton, A N; Old, L J (1985) Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A 82:1470-4
Real, F X; Houghton, A N; Albino, A P et al. (1985) Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 45:4401-11